RANI.US Rani Therapeutics Holdings Inc

Healthcare Biotechnology USA Stocks
0.5594 USD
Close of Nov 18, 2026
0.5020 1.82
Market cap
USD 64.6M
P/E
-
P/B
1.88x
ROE
-86.9%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.

Is RANI.US undervalued?

Graham number

The Graham number of Rani Therapeutics Holdings Inc cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Rani Therapeutics Holdings Inc fundamental analysis

No fundamental analysis for Rani Therapeutics Holdings Inc yet.

Rani Therapeutics Holdings Inc stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Rani Therapeutics Holdings Inc

Rani Therapeutics Holdings, Inc. operates as a clinical stage biotherapeutics company, focusing on technologies to enable the administration of biologics and drugs orally for patients, physicians, and healthcare systems with a alternative to painful injections in the United States. The company develops the RaniPill capsule, a drug-agnostic oral delivery platform to deliver a variety of drug substances, including oligonucleotides, peptides, proteins, and antibodies. Its produ…

Full company profile